317 related articles for article (PubMed ID: 9452489)
21. An O-GlcNAcase-specific inhibitor and substrate engineered by the extension of the N-acetyl moiety.
Kim EJ; Perreira M; Thomas CJ; Hanover JA
J Am Chem Soc; 2006 Apr; 128(13):4234-5. PubMed ID: 16568991
[TBL] [Abstract][Full Text] [Related]
22. Protein O-GlcNAc modulates motility-associated signaling intermediates in neutrophils.
Kneass ZT; Marchase RB
J Biol Chem; 2005 Apr; 280(15):14579-85. PubMed ID: 15703172
[TBL] [Abstract][Full Text] [Related]
23. Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury.
Xing D; Feng W; Nöt LG; Miller AP; Zhang Y; Chen YF; Majid-Hassan E; Chatham JC; Oparil S
Am J Physiol Heart Circ Physiol; 2008 Jul; 295(1):H335-42. PubMed ID: 18469144
[TBL] [Abstract][Full Text] [Related]
24. Glucosamine modulates TNF-α-induced ICAM-1 expression and function through O-linked and N-linked glycosylation in human retinal pigment epithelial cells.
Chen CL; Liang CM; Chen YH; Tai MC; Lu DW; Chen JT
Invest Ophthalmol Vis Sci; 2012 Apr; 53(4):2281-91. PubMed ID: 22427561
[TBL] [Abstract][Full Text] [Related]
25. O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress.
Zachara NE; Hart GW
Biochim Biophys Acta; 2004 Jul; 1673(1-2):13-28. PubMed ID: 15238246
[TBL] [Abstract][Full Text] [Related]
26. The synthesis and biological evaluation of some carbocyclic analogues of PUGNAc.
Scaffidi A; Stubbs KA; Vocadlo DJ; Stick RV
Carbohydr Res; 2008 Nov; 343(16):2744-53. PubMed ID: 18804755
[TBL] [Abstract][Full Text] [Related]
27. A divergent synthesis of 2-acyl derivatives of PUGNAc yields selective inhibitors of O-GlcNAcase.
Stubbs KA; Zhang N; Vocadlo DJ
Org Biomol Chem; 2006 Mar; 4(5):839-45. PubMed ID: 16493467
[TBL] [Abstract][Full Text] [Related]
28. Proteomics and PUGNAcity will overcome questioning of insulin resistance induction by nonselective inhibition of O-GlcNAcase.
Dehennaut V; Lefebvre T
Proteomics; 2013 Oct; 13(20):2944-6. PubMed ID: 23983178
[TBL] [Abstract][Full Text] [Related]
29. Insight into a strategy for attenuating AmpC-mediated beta-lactam resistance: structural basis for selective inhibition of the glycoside hydrolase NagZ.
Balcewich MD; Stubbs KA; He Y; James TW; Davies GJ; Vocadlo DJ; Mark BL
Protein Sci; 2009 Jul; 18(7):1541-51. PubMed ID: 19499593
[TBL] [Abstract][Full Text] [Related]
30. O-GlcNAc signaling attenuates ER stress-induced cardiomyocyte death.
Ngoh GA; Hamid T; Prabhu SD; Jones SP
Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1711-9. PubMed ID: 19734355
[TBL] [Abstract][Full Text] [Related]
31. Identification of a specific inhibitor of nOGA - a caspase-3 cleaved O-GlcNAcase variant during apoptosis.
Li J; Li Z; Li T; Lin L; Zhang Y; Guo L; Xu Y; Zhao W; Wang P
Biochemistry (Mosc); 2012 Feb; 77(2):194-200. PubMed ID: 22348480
[TBL] [Abstract][Full Text] [Related]
32. PUGNAc induces protein ubiquitination in C2C12 myotube cells.
Park JH; Lee JE; Moon PG; Baek MC
Cell Biochem Funct; 2015 Dec; 33(8):525-33. PubMed ID: 26531776
[TBL] [Abstract][Full Text] [Related]
33. O-GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors.
Macauley MS; Whitworth GE; Debowski AW; Chin D; Vocadlo DJ
J Biol Chem; 2005 Jul; 280(27):25313-22. PubMed ID: 15795231
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy.
Yokoe S; Asahi M; Takeda T; Otsu K; Taniguchi N; Miyoshi E; Suzuki K
Glycobiology; 2010 Oct; 20(10):1217-26. PubMed ID: 20484118
[TBL] [Abstract][Full Text] [Related]
35. Hyper-O-GlcNAcylation inhibits the induction of heat shock protein 70 (Hsp 70) by sodium arsenite in HeLa cells.
Miura Y; Sato T; Sakurai Y; Sakai R; Hiraoka W; Endo T
Biol Pharm Bull; 2014; 37(8):1308-14. PubMed ID: 25087952
[TBL] [Abstract][Full Text] [Related]
36. Increasing O-GlcNAc levels: An overview of small-molecule inhibitors of O-GlcNAcase.
Macauley MS; Vocadlo DJ
Biochim Biophys Acta; 2010 Feb; 1800(2):107-21. PubMed ID: 19664691
[TBL] [Abstract][Full Text] [Related]
37. Proteomic approaches to analyze the dynamic relationships between nucleocytoplasmic protein glycosylation and phosphorylation.
Whelan SA; Hart GW
Circ Res; 2003 Nov; 93(11):1047-58. PubMed ID: 14645135
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of chitinolytic activities from tree species and associated fungi.
Hodge A; Gooday GW; Alexander IJ
Phytochemistry; 1996 Jan; 41(1):77-84. PubMed ID: 8588878
[TBL] [Abstract][Full Text] [Related]
39. Computational analysis of human OGA structure in complex with PUGNAc and NAG-thiazoline derivatives.
de Alencar NA; Sousa PR; Silva JR; Lameira J; Alves CN; Martí S; Moliner V
J Chem Inf Model; 2012 Oct; 52(10):2775-83. PubMed ID: 22937904
[TBL] [Abstract][Full Text] [Related]
40. O-GlcNAc modification of NFκB p65 inhibits TNF-α-induced inflammatory mediator expression in rat aortic smooth muscle cells.
Xing D; Gong K; Feng W; Nozell SE; Chen YF; Chatham JC; Oparil S
PLoS One; 2011; 6(8):e24021. PubMed ID: 21904602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
